Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Mangoceuticals Stock Up 3.8%

NASDAQ:MGRX opened at $1.64 on Friday. The company has a fifty day moving average of $1.73 and a 200-day moving average of $2.46. The firm has a market capitalization of $8.48 million, a P/E ratio of -0.42 and a beta of 2.42. Mangoceuticals has a twelve month low of $1.32 and a twelve month high of $7.66.

Mangoceuticals (NASDAQ:MGRX) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.57) earnings per share for the quarter. The company had revenue of $0.17 million during the quarter. Mangoceuticals had a negative net margin of 2,757.86% and a negative return on equity of 89.54%.

Institutional Trading of Mangoceuticals

An institutional investor recently raised its position in Mangoceuticals stock. Geode Capital Management LLC raised its holdings in shares of Mangoceuticals, Inc. (NASDAQ:MGRX) by 35.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,498 shares of the company’s stock after purchasing an additional 6,928 shares during the quarter. Geode Capital Management LLC owned 0.51% of Mangoceuticals worth $40,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.